Verition Fund Management
XERS icon

Verition Fund Management’s Xeris Biopharma Holdings XERS Stock Holding History

Verition Fund Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,229
Closed -$99.5K – 4005
2025
Q3 		$99.5K Buy
+12,229
New +$81.2K ﹤0.01% 3602
2025
Q2 		– Sell
-41,290
Closed -$227K – 3905
2025
Q1 		$227K Sell
41,290
-43,920
-52% -$177K ﹤0.01% 3002
2024
Q4 		$289K Buy
85,210
+8,700
+11% +$28K ﹤0.01% 2795
2024
Q3 		$218K Buy
76,510
+2,276
+3% +$5.84K ﹤0.01% 2829
2024
Q2 		$167K Buy
+74,234
New +$150K ﹤0.01% 2649
2023
Q4 		– Sell
-24,700
Closed -$45.9K – 2722
2023
Q3 		$45.9K Sell
24,700
-12,308
-33% -$28.2K ﹤0.01% 2191
2023
Q2 		$97K Buy
+37,008
New +$94.2K ﹤0.01% 1981
2022
Q4 		– Sell
-12,666
Closed -$20K – 2826
2022
Q3 		$20K Hold
12,666
– – ﹤0.01% 2787
2022
Q2 		$20K Buy
+12,666
New +$26.7K ﹤0.01% 2215

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Verition Fund Management's XERS Position: Q4 2025 in Review

Verition Fund Management sold out of Xeris Biopharma Holdings (XERS) in Q4 2025, closing a stake of 12,229 shares — an estimated $99.5K sold.

Verition Fund Management first reported a position in XERS in Q2 2022 and held it in 9 quarters. The position peaked at $289K in Q4 2024. 225 funds tracked by Wall St. Rank hold XERS as of Q4 2025.

  • Verition Fund Management reported no remaining Xeris Biopharma Holdings position as of Q4 2025 after selling out during the quarter.
  • Verition Fund Management sold 12,229 Xeris Biopharma Holdings shares in Q4 2025, an estimated $99.5K.
  • Verition Fund Management first reported a position in Xeris Biopharma Holdings in Q2 2022 and held it in 9 quarters.
  • Verition Fund Management's Xeris Biopharma Holdings position peaked at $289K in Q4 2024.
  • 225 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q4 2025.

Based on Verition Fund Management's 13F filing for Q4 2025, filed 13 Feb 2026.